2021
DOI: 10.1101/2021.05.26.21257063
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test in symptomatic populations and asymptomatic community testing

Abstract: Background As the COVID-19 pandemic continues to cause substantial morbidity and mortality, there is an increased need for rapid, accessible assays for SARS-CoV-2 detection. Methods Here we present a clinical evaluation and real-world implementation of the INDICAID COVID-19 Rapid Antigen Test (INDICAID Rapid Test). A multi-site clinical evaluation of the INDICAID Rapid Test using prospectively collected samples from symptomatic subjects was performed. The INDICAID Rapid Test was then implemented at COVID-19 … Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 8 publications
0
1
0
Order By: Relevance
“…Samples for the INDICAID™ Ag-RDT were processed immediately on-site after collection with no storage as per the manufacturer's protocol. Results of the INDICAID™ Ag-RDT were interpreted by the test operators and recorded as "Positive," "Negative", or "Invalid" based on the visual presence or absence of the control and test lines on the developed test strip after 20 min [ [23] , [28] ].…”
Section: Methodsmentioning
confidence: 99%
“…Samples for the INDICAID™ Ag-RDT were processed immediately on-site after collection with no storage as per the manufacturer's protocol. Results of the INDICAID™ Ag-RDT were interpreted by the test operators and recorded as "Positive," "Negative", or "Invalid" based on the visual presence or absence of the control and test lines on the developed test strip after 20 min [ [23] , [28] ].…”
Section: Methodsmentioning
confidence: 99%